Literature DB >> 15662593

Levels of plasma fibrinogen and d-dimer in patients with impaired fasting glucose.

E Coban1, R Sari, M Ozdogan, F Akcit.   

Abstract

BACKGROUND: Cardiovascular risk associated with impaired fasting glucose has been examined in various studies with conflicting results. During the last 10 years, several risk markers for atherosclerosis such as fibrinogen and D-dimer have been identified. The present study was designed to evaluate plasma fibrinogen and D-dimer levels in patients with impaired fasting glucose compared with normal subjects and those with type 2 diabetes mellitus.
METHODS: Age-, sex-, and body mass index-matched 30 normal subjects, 30 patients with impaired fasting glucose (fasting glucose 110 to 125 mg/dl), and 30 patients with type 2 diabetes mellitus (fasting glucose >/= 126 mg/dl) were included in the study.
RESULTS: The levels of plasma fibrinogen in patients with type 2 diabetes mellitus, impaired fasting glucose, and normal subjects were 449 (306 - 605) mg/dl, 348 (264 - 468) mg/dl, and 216 (179 - 260) mg/dl, respectively. Patients with impaired fasting glucose had significantly lower plasma fibrinogen levels than patients with type 2 diabetes mellitus (p < 0.05). There were significantly higher plasma fibrinogen levels in patients with impaired fasting glucose than in normal subjects (p < 0.05). The levels of plasma D-dimer in patients with type 2 diabetes mellitus, impaired fasting glucose, and normal subjects were 615 (505 - 768) mg/l, 518 (412 - 664) mg/l, and 424 (356 - 557) mg/l, respectively. Patients with impaired fasting glucose had significantly lower plasma D-dimer levels than patients with type 2 diabetes mellitus (p < 0.05). There were significantly higher plasma D-dimer levels in patients with impaired fasting glucose than in normal subjects (p < 0.05). The levels of plasma fibrinogen and D-dimer were related to fasting glucose in type 2 diabetes mellitus and impaired fasting glucose groups (p < 0.05). We also detected positive correlation between plasma fibrinogen levels and age in study groups (p < 0.05).
CONCLUSION: Our data suggest that patients with impaired fasting glucose pose a hypofibrinolytic status and cardiovascular risk, although this was lower than in patients with type 2 diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15662593     DOI: 10.1055/s-2004-830524

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  5 in total

1.  GDF15 Is a Novel Biomarker for Impaired Fasting Glucose.

Authors:  Jun Hwa Hong; Hyo Kyun Chung; Hye Yoon Park; Kyong-Hye Joung; Ju Hee Lee; Jin Gyu Jung; Koon Soon Kim; Hyun Jin Kim; Bon Jeong Ku; Minho Shong
Journal:  Diabetes Metab J       Date:  2014-12-15       Impact factor: 5.376

2.  The Value of Combining Plasma D-Dimer and Endothelin-1 Levels to Predict No-Reflow After Percutaneous Coronary Intervention of ST-Segment Elevation in Acute Myocardial Infarction Patients with a Type 2 Diabetes Mellitus History.

Authors:  Ronghua Gao; Jianjun Wang; Shaohui Zhang; Guoliang Yang; Zhencai Gao; Xueying Chen
Journal:  Med Sci Monit       Date:  2018-05-28

3.  D-dimer, COVID-19 and Diabetes: A Correspondence.

Authors:  Sora Yasri; Viroj Wiwanitkit
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

4.  Increased plasma D-dimer levels may be a promising indicator for diabetic peripheral neuropathy in type 2 diabetes.

Authors:  Lei Zhuang; Chao Yu; Feng Xu; Li-Hua Zhao; Xiao-Hua Wang; Chun-Hua Wang; Li-Yan Ning; Xiu-Lin Zhang; Dong-Mei Zhang; Xue-Qin Wang; Jian-Bin Su
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-23       Impact factor: 6.055

5.  Fibrinogen function indexes are potential biomarkers of diabetic peripheral neuropathy.

Authors:  Yong Zhuang; Xiahong Lin; Xiaoyu Chen; Xiaohong Wu; Jinying Zhang
Journal:  Diabetol Metab Syndr       Date:  2022-01-18       Impact factor: 3.320

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.